What's Going On With Merck Stock On Friday?
What's Going On With Merck Stock On Friday?
On Thursday, the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Merck & Co Inc's (NYSE:MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years of age and older. It is also commonly known as the pneumonia vaccine.
週四，美國疾病控制與預防中心免疫實踐諮詢委員會一致投票推薦默沙東公司（紐交所代碼：MRK）Capvaxive（肺炎球菌21價結合疫苗）推薦給65歲以上的成年人，也常被稱爲肺炎疫苗。
Specifically, the ACIP voted to recommend a single dose of Capvaxive for:
具體來說，ACIP建議爲以下這些人推薦單劑量的Capvaxive：
- Adults 65 years and older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.
- Adults 19-64 years of age with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.
- Adults 19 years and older who have started their pneumococcal vaccine series with PCV13 (pneumococcal 13-valent conjugate vaccine) but have not received all recommended PPSV23 (pneumococcal 23-valent polysaccharide vaccine) doses.
- 年齡在65歲及以上的成年人，未曾接種肺炎球菌結合疫苗或疫苗接種史未知的人。
- 19-64歲、具有特定潛在醫學條件或其他風險因素、未曾接種肺炎球菌結合疫苗或疫苗接種史未知的成年人。
- 已開始接種肺炎球菌疫苗系列，使用了PCV13（肺炎球菌13價結合疫苗），但未接受所有建議的PPSV23（肺炎球菌23價多糖疫苗）劑量的19歲及以上成年人。
Additionally, shared clinical decision-making is recommended regarding the use of a supplemental dose of Capvaxive for adults 65 years and older who have completed their vaccine series with both PCV13 and PPSV23.
此外，對於年齡在65歲及以上、已完成PCV13和PPSV23疫苗系列接種的成年人，建議共同進行臨床決策，以使用Capvaxive的補充劑量。
Friday, Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended the approval of Winrevair (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies for adult PAH patients with World Health Organization Functional Class II to III, to improve exercise capacity.
默沙東周五宣佈，歐洲藥品管理局人用藥品委員會（CHMP）推薦批准Winrevair（Sotatercept），聯合其他肺動脈高壓（PAH）療法治療世界衛生組織功能分級爲II到III級的成年PAH患者，以提高運動能力。
The European Commission (EC) will now review the CHMP recommendation. The EC's decision on Winrevair's marketing authorization application is expected in the third quarter of 2024.
歐洲委員會（EC）將現在評審CHMP的建議。預計EC將於2024年第三季度就Winrevair的上市許可申請作出決定。
The CHMP recommendation is based on data from the Phase 3 STELLAR trial of Winrevair on top of background PAH therapy compared to background therapy alone.
CHMP的建議基於Winrevair的III期STELLAR試驗數據，該試驗對背景PAH療法加上Winrevair與背景療法單獨相比進行了比較。
Winrevair demonstrated a statistically significant and clinically meaningful improvement in the 6-minute walk distance, the study's primary endpoint, and on multiple important secondary outcome measures, including reducing the risk of death from any cause or PAH clinical worsening events.
Winrevair在6分鐘步行距離以及多個重要的二級終點指標方面表現出了具有統計學意義的臨床意義，並減少了任何原因或PAH臨床惡化事件的死亡風險。
Also Read: FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug.
還閱讀：FDA拒絕批准默沙東與第一三共合作的肺癌藥物。
Price Action: MRK shares were trading higher by 0.13% at $129.99 premarket at the last check on Friday.
截至週五，MRK股價於盤前交易時上漲了0.13%，報129.99美元。
Photo via Unsplash
照片來自Unsplash
譯文內容由第三人軟體翻譯。